Attend the FierceBiotech Executive Breakfast at BIO 2019
Join us on June 5th for our panel discussion on real-world evidence. Reserve your seat today.
A Lithuanian CDMO is investing €50 million in its biologics manufacturing site and adding up to 80 jobs.
Chinese CDMO GenScript Biotech has started construction on a production facility to specialize in plasmids and viruses manufacturing.
Smoke from a fire set off by welding sparks reportedly killed 10 workers and injured a dozen rescuers at a pharmaceutical plant in China.
Ajinomoto Bio-Pharma Services has concluded a deal that will allow the CDMO to operate in the gene therapy space.
In the second major buyout of a gene therapy manufacturer in the last three weeks, Catalent snapped up Paragon Bioservices in a $1.2 billion deal.
With drug development in China growing rapidly, Catalent has doubled down on its clinical supply capabilities in Shanghai.
Cambrex will have a new U.S. facility capable of producing high-potency APIs ready and running in May.
A man who made tens of millions of dollars selling gray-market drugs in the U.S. has been sentenced to 30 years in federal prison.
Fresenius Kabi missed an opportunity to quickly bulk up in sterile manufacturing when its $5 billion deal to buy Akorn imploded last year.
Even as Aurobindo grows its footprint in the U.S., the FDA continues to find problems in its manufacturing.